EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps

Sulaiman Bani Abdel-Rahman, Hala Altarawneh, Mohammed Abu Lubad, Hamed Alzoubi, Khulud A Alhazmi, Ohood S Alharbi, Malaz Gazzaz, Mohanned Talal Alharbi, Rawan Altalhi, Waiel S Halabi, Asim T Sharif, Bayan Redwan und 14 weitere

The Journal of Infection in Developing Countries · 30.06.2026 · 20 (06) · 802-809

DOI: 10.3855/jidc.21822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, online erschienen am 30.06.2026. Verfasst von Sulaiman Bani Abdel-Rahman und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7, Mutah, Al-Karak, 61710, Jordan. Hauptthemen laut MEDLINE: Cisplatin, Anti-Bacterial Agents, Gram-Positive Bacteria. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Multidrug resistant (MDR) bacteria are one of the most important current threats to public health. Therefore, serious concerns were raised about the effectiveness of traditional antibiotics. Cisplatin, a chemotherapeutic agent that is used mainly in cancer treatment, has recently attracted attention and popularity for its potential antibacterial properties. Our study aim is to evaluate the antibacterial properties of cisplatin against several common MDR and non-MDR Gram-positive strains, including Methicillin-Resistant Staphylococcus aureus (MRSA), Methicillin-Susceptible Staphylococcus aureus (MSSA), Coagulase-Negative Staphylococcus (CoNS), and Vancomycin-Resistant Enterococcus (VRE). Methodology: Cisplatin's Minimum Inhibitory Concentration (MIC) was calculated through standard microdilution methods.

Results

Our findings indicated that cisplatin had a minimum inhibitory concentration (MIC) of 256 µg/mL across all tested bacterial strains, reflecting its limited antibacterial efficacy in its currently available formulation. However, although the MIC values were high, this study explored cisplatin’s activity against these bacterial strains which uncovers a potential gap about cisplatin clinical effectiveness and indicates that further enhancement is required.

Conclusions

These results confirm that cisplatin antibacterial activity has not been extensively explored against these resistant strains. Cisplatin alone shows limited efficacy based on the relatively high MIC values observed. However, combination therapy with other antibiotics may improve its therapeutic potential. Additionally, novel delivery systems—nanoparticle formulations, for instance—could enhance antibacterial activity while reducing toxicity. Future investigations should evaluate these approaches in more detail.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinAnti-Bacterial AgentsGram-Positive BacteriaMicrobial Sensitivity TestsHumansDrug Resistance, Multiple, BacterialStaphylococcusMethicillin-Resistant Staphylococcus aureusGram-Positive Bacterial Infections

Stichwörter der Autor:innen

CisplatinMICMRSAMultidrug-resistant bacteriaVRE

Substanzen

CisplatinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Microbiology and Pathology, Faculty of Medicine, Mutah University, P.O. Box 7, Mutah, Al-Karak, 61710, Jordan.
  • Department of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
  • Department of Microbiology and Parasitology, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Pharmaceutical Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
  • Department of Basic Medical Sciences, College of Medicine, University of Jeddah, Jeddah, Saudi Arabia.
  • Department of Biological Sciences, College of Science, University of Jeddah, Jeddah 23445, Saudi Arabia.

Zitieren

APA

Bani Abdel-Rahman, S., Altarawneh, H., Abu Lubad, M., Alzoubi, H., Alhazmi, K. A., Alharbi, O. S., Gazzaz, M., Alharbi, M. T., Altalhi, R., Halabi, W. S., Sharif, A. T., Redwan, B., Ismail, M. A., Sait, A. M., Alkuwaity, K., Alhazmi, W., Alfawaz, S. A., Daghistani, H., Saleh, B. H., …, & Ibrahem, K. (2026). Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps. The Journal of Infection in Developing Countries, 20(06), 802-809. https://doi.org/10.3855/jidc.21822

Vancouver

Bani Abdel-Rahman S, Altarawneh H, Abu Lubad M, Alzoubi H, Alhazmi KA, Alharbi OS, et al. Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps. The Journal of Infection in Developing Countries. 2026;20(06):802-809. doi:10.3855/jidc.21822

BibTeX
@article{BaniAbdelRahman2026,
  author = {Bani Abdel-Rahman, Sulaiman and Altarawneh, Hala and Abu Lubad, Mohammed and Alzoubi, Hamed and Alhazmi, Khulud A and Alharbi, Ohood S and Gazzaz, Malaz and Alharbi, Mohanned Talal and Altalhi, Rawan and Halabi, Waiel S and Sharif, Asim T and Redwan, Bayan and Ismail, Mazen A and Sait, Ahmad M and Alkuwaity, Khalil and Alhazmi, Wafaa and Alfawaz, Sultan A and Daghistani, Hussam and Saleh, Bandar Hasan and Alqarni, Mona Abdulrahman and Alsaedi, Abdulaziz and Alhussainy, Nabeel Hussain and Niyazi, Hatoon A and Niyazi, Hanouf A and Attallah, Dalya M and Ibrahem, Karem},
  title = {Characterizing the antimicrobial activity of cisplatin against Gram-positive clinical strains: bridging existing gaps},
  journal = {The Journal of Infection in Developing Countries},
  year = {2026},
  volume = {20},
  number = {06},
  pages = {802--809},
  doi = {10.3855/jidc.21822}
}
Kostenlos starten →